

NEUROFIBROMATOSIS (NF) RESEARCH PROGRAM




CDMRP
DEPARTMENT OF DEFENSE
CONGRESSIONALLY DIRECTED
MEDICAL RESEARCH PROGRAMS

VISION: DECREASE THE CLINICAL IMPACT OF NEUROFIBROMATOSIS

Mission: Promote research directed toward the understanding, diagnosis, and treatment of NF1, NF2, and schwannomatosis to enhance the quality of life for persons with these disorders that impact Service Members, Veterans, and the general public

**FY23
Funding
\$25M**

FY23 NFRP Mechanisms and Funding Amounts




FY23 NFRP Application Deadlines

- August 11, 2023**
Letter of Intent Submission Deadline
- August 25, 2023**
Application Submission Deadline
- October 2023**
Peer Review
- January/February 2024**
Programmatic Review

FY23 NFRP Areas of Emphasis

- NF2 and Schwannomatosis-related areas (e.g., hearing, balance, schwannoma, ependymoma, meningioma, LZTR1, SMARCB1)
- Endpoint validation, biomarker discovery, and technological innovation for assessments
- Application of data science
- Non-tumor manifestations not limited to pain, cognitive manifestations, sleep
- Heterogeneity of NF-related phenotypes
- Genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches
- Preclinical efficacy studies
- Target identification and drug discovery
- Nutritional, environmental, and other modifiers of NF
- Health services research

FY96–FY22 Investment Pie Chart



For more information on the NFRP, please visit the CDMRP website:
cdmrp.army.mil/nfrp

